FDA-approved kinase inhibitors: a promising therapeutic avenue for traumatic brain injury
Traumatic brain injury (TBI) is a complex disease that leads to significant mortality and disability worldwide each year. TBI disrupts the normal activity of kinases and molecular signaling pathways, but the effective therapeutic methods for patients remain limited. Nowadays, kinase inhibitors appro...
Saved in:
Main Authors: | Dezhu Gao, Yu Shi, Zhiliang Wang, Weiming Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Open Exploration
2024-12-01
|
Series: | Exploration of Drug Science |
Subjects: | |
Online Access: | https://www.explorationpub.com/uploads/Article/A100877/100877.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antioxidant and Anti-Inflammatory Properties of Melatonin in Secondary Traumatic Brain Injury
by: Mariusz Sieminski, et al.
Published: (2024-12-01) -
Navigating the depths: A comprehensive narrative review on depression in people with epilepsy
by: Norah A. Alkhaldi
Published: (2025-01-01) -
Ivermectin as a promising therapeutic option for onchocerciasis‐associated epilepsy
by: Mohammad Amin Manavi, et al.
Published: (2025-02-01) -
Psychosis of Epilepsy: An Update on Clinical Classification and Mechanism
by: Zhiruo Qiu, et al.
Published: (2025-01-01) -
Treatment of traumatic endophthalmitis: A case report
by: Yongqiang Li, et al.
Published: (2025-02-01)